cd137 x ta binding molecule, pharmaceutical compositions, use of cd137 x ta binding molecule, cd137 binding molecule, use of cd137 binding molecule, her2 / neu binding molecule, use of her2 binding molecule / neu, and use of a composition

摘要

the present invention relates to binding molecules that have one or more epitope binding sites specific to a cd137 epitope and one or more epitope binding sites specific to a tumor antigen (ta) epitope (i.e., a molecule binding to cd137 x ta). in one embodiment, these cd137 x ta binding molecules will be bispecific molecules, especially bispecific tetravalent diabody, which are composed of two, three, four or more than four polypeptide chains and which have two epitope-binding sites each specific to an epitope of cd137 and two epitope binding sites each specific for a one-epitope. alternatively, these cd137 x ta binding molecules will be bispecific molecules, especially bispecific trivalent binding molecules composed of three or more polypeptide chains and having one or two epitope binding sites each specific for a cd137 epitope and one or two sites binding to epitope each specific to an epitope of a ta. the cd137 x ta binding molecules of the invention are capable of binding simultaneously to cd137 and a ta. the invention relates to pharmaceutical compositions that contain any of these cd137xta binding molecules. the invention further relates to methods for using these molecules in the treatment of cancer and other diseases and conditions. the invention also provides new cd137 binding molecules, and her2 / neu binding molecules, as well as derivatives thereof and their uses.